A New Urticaria Biomarker Contradicts the Last One

A study set for online publication September 6, 2026 in the Journal of the American Academy of Dermatology reports that patients with chronic spontaneous urticaria who carry higher circulating levels of MRGPRX2, a mast-cell receptor, respond worse to antihistamines. The finding, credited to Zhao Wang, Yuanyuan Ding, Dan Ye, Chao Wang, Tao Zhang, and Songmei Geng, points to a biomarker that could in theory tell clinicians early which patients will fail standard treatment and need to move faster toward biologics.

That would matter because antihistamine failure in chronic spontaneous urticaria is routine rather than rare. Guideline literature synthesized by EAACI, GA2LEN, EDF, EuroGuiDerm, and APAAACI puts the share of patients who don't achieve full control on licensed doses at roughly half to sixty percent, and even after the guideline-recommended step of quadrupling the antihistamine dose, meta-analyses put response around 63 percent, meaning close to a third of patients are still symptomatic. The current treatment ladder runs from standard-dose antihistamine to updosing to omalizumab to cyclosporine or other immunomodulators, and a biomarker that flags likely failure early could let a clinician skip a step.

The trouble is that a separate prospective study, published in Scientific Reports in 2025, measured the same molecule in severe chronic spontaneous urticaria patients and reached a different conclusion. Its title states the finding directly: serum MRGPRX2 and substance P levels are biomarkers of disease activity rather than an antihistamine response. In that cohort, circulating MRGPRX2 tracked with how severe a patient's disease was, but it did not predict whether antihistamines would work. The JAAD-bound paper and the Scientific Reports paper are looking at the same receptor in the same disease and landing on opposite claims about what it forecasts.

Neither paper's full text is available here for direct comparison, so it isn't yet clear whether the discrepancy comes from different patient cohorts, different MRGPRX2 cutoff values, or different definitions of what counts as an antihistamine response. Severity and treatment resistance often move together in urticaria research, which makes them easy to conflate in a single serum measurement. Until both study populations and thresholds are laid side by side, a reader should treat the new paper's association as a single result awaiting replication rather than as a settled biomarker.

The mechanistic case for MRGPRX2 mattering is real: it is a mast-cell-restricted receptor that triggers degranulation independent of IgE, which would explain why it might escape drugs built around that pathway. Antihistamines block the H1 receptor downstream of mediator release, and omalizumab works through IgE and its receptor, so neither directly touches MRGPRX2 signaling. But the field's history with this receptor also carries a caution. A 2025 paper in the Journal of Allergy and Clinical Immunology reported a gain-of-function MRGPRX2 variant, 185A>G or N62S, enriched in patients with more active disease. A subsequent JACI correspondence pushed back, noting the variant's allele frequency runs 30 to 40 percent in the general population and in drug-hypersensitivity control groups alike, that the original study had no control population, and that the same polymorphism turns up in both reactive and tolerant people.

Even a validated MRGPRX2 signal would currently point toward a drug that isn't available. Incyte's EP262, the oral MRGPRX2 antagonist it acquired along with Escient Pharmaceuticals for $750 million in April 2024, was the most advanced compound built around this exact target, with a Phase 2 trial in chronic spontaneous urticaria registered as NCT06077773. In 2025 Incyte paused part of that trial after in vivo preclinical toxicology findings unrelated to MRGPRX2 pharmacology at expected human doses, disclosed the finding to the FDA, and saw its stock drop on the news. The receptor identified as a biomarker of drug resistance is, for now, a target without a working antagonist behind it.